| Entry |
|
|---|
| Name |
OnabotulinumtoxinA (USAN);
EvabotulinumtoxinA (USAN);
Botox (TN) |
|---|
| Product |
|
|---|
| Formula |
C6708 H10363N1729O1995S32
|
|---|
| Exact mass |
148084.3667
|
|---|
| Mol weight |
148175.57
|
|---|
| Sequence |
(Light chain)
PFVNKQFNYK DPVNGVDIAY IKIPNAGQMQ PVKAFKIHNK IWVIPERDTF TNPEEGDLNP
PPEAKQVPVS YYDSTYLSTD NEKDNYLKGV TKLFERIYST DLGRMLLTSI VRGIPFWGGS
TIDTELKVID TNCINVIQPD GSYRSEELNL VIIGPSADII QFECKSFGHE VLNLTRNGYG
STQYIRFSPD FTFGFEESLE VDTNPLLGAG KFATDPAVTL AHELIHAGHR LYGIAINPNR
VFKVNTNAYY EMSGLEVSFE ELRTFGGHDA KFIDSLQENE FRLYYYNKFK DIASTLNKAK
SIVGTTASLQ YMKNVFKEKY LLSEDTSGKF SVDKLKFDKL YKMLTEIYTE DNFVKFFKVL
NRKTYLNFDK AVFKINIVPK VNYTIYDGFN LRNTNLAANF NGQNTEINNM NFTKLKNFTG
LFEFYKLLCV RGIITSK
(Heavy chain)
ALNDLCIKVN NWDLFFSPSE DNFTNDLNKG EEITSDTNIE AAEENISLDL IQQYYLTFNF
DNEPENISIE NLSSDIIGQL ELMPNIERFP NGKKYELDKY TMFHYLRAQE FEHGKSRIAL
TNSVNEALLN PSRVYTFFSS DYVKKVNKAT EAAMFLGWVE QLVYDFTDET SEVSTTDKIA
DITIIIPYIG PALNIGNMLY KDDFVGALIF SGAVILLEFI PEIAIPVLGT FALVSYIANK
VLTVQTIDNA LSKRNEKWDE VYKYIVTNWL AKVNTQIDLI RKKMKEALEN QAEATKAIIN
YQYNQYTEEE KNNINFNIDD LSSKLNESIN KAMININKFL NQCSVSYLMN SMIPYGVKRL
EDFDASLKDA LLKYIYDNRG TLIGQVDRLK DKVNNTLSTD IPFQLSKYVD NQRLLSTFTE
YIKNIINTSI LNLRYESNHL IDLSRYASKI NIGSKVNFDP IDKNQIQLFN LESSKIEVIL
KNAIVYNSMY ENFSTSFWIR IPKYFNSISL NNEYTIINCM ENNSGWKVSL NYGEIIWTLQ
DTQEIKQRVV FKYSQMINIS DYINRWIFVT ITNNRLNNSK IYINGRLIDQ KPISNLGNIH
ASNNIMFKLD GCRDTHRYIW IKYFNLFDKE LNEKEIKDLY DNQSNSGILK DFWGDYLQYD
KPYYMLNLYD PNKYVDVNNV GIRGYMYLKG PRGSVMTTNI YLNSSLYRGT KFIIKKYASG
NKDNIVRNND RVYINVVVKN KEYRLATNAS QAGVEKILSA LEIPDVGNLS QVVVMKSKND
QGITNKCKMN LQDNNGNDIG FIGFHQFNNI AKLVASNWYN RQIERSSRTL GCSWEFIPVD
DGWGERPL |
|---|
| Type |
Peptide |
|---|
| Class |
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG01696 Peripherally-acting muscle relaxant
DG03117 Nondepolarizing neuromuscular blocking agent
|
|---|
| Remark |
| Product (DG00772): | D00783<JP/US> D02735<US> D11405<US> D08957<US> D10012<JP/US> D10949<US> |
|
|---|
| Efficacy |
Antimigraine, Skeletal muscle relaxant |
|---|
| Disease |
|
|---|
| Comment |
Treatment of cervical dystonia, severe primary axillary hyperhidrosis, Glabellar lines, blepharospasm, strabismus, Treatment of adult onset spasmodic torticollis/cervical dystonia, Reduction of glabellar rhytides
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M03 MUSCLE RELAXANTS
M03A MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03AX Other muscle relaxants, peripherally acting agents
M03AX01 Botulinum toxin
D08957 OnabotulinumtoxinA (USAN) <US>
USP drug classification [BR:br08302]
Dermatological Agents
Dermatological Agents, Other
Dermatological Agents, Miscellaneous
Onabotulinumtoxin A
D08957 OnabotulinumtoxinA (USAN)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG01696 Peripherally-acting muscle relaxant
DG03117 Nondepolarizing neuromuscular blocking agent
DG00772 Botulinum toxin
D08957 OnabotulinumtoxinA
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG01696 Peripherally-acting muscle relaxant
DG03117 Nondepolarizing neuromuscular blocking agent
DG00772 Botulinum toxin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
